• Small Molecules
      • Discovery
    • Large Molecules
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers

News & Events

Syngene reports revenue from operations up 8% in the first quarter
20th Jul, 2022
Syngene signs 10-year biologics manufacturing agreement with leading animal health company, Zoetis
14th Jul, 2022
Syngene reports full year revenue from operations up 19% to Rs. 2604 Cr
27th Apr, 2022
Syngene International takes top honors at CMO Leadership Awards 2022 for contract manufacturing
9th Mar, 2022
Syngene releases its first ESG report for FY2020-21 in accordance with the Global Reporting Initiative (GRI)
24th Feb, 2022
Syngene reports 10% growth in revenue from operations to Rs.6,414 Mn and raises full-year guidance
19th Jan, 2022
Syngene International Announces Extension of Collaboration with Amgen
16th Dec, 2021
Syngene through Biocon Foundation partners with NIMHANS for BHUMI
10th Dec, 2021
Syngene reports second quarter results Revenue from operations up 17% to Rs. 6,102 Mn, PAT increased 9% to Rs. 920 Mn
20th Oct, 2021
Syngene expands biopharma-manufacturing capacity. Sets up a state-of-the-art microbial facility; expands mammalian facility
12th Aug, 2021
Syngene announces senior-level appointments Strengthens leadership in USA
4th Aug, 2021
Syngene reports first quarter results Revenue from operations up 41% to Rs. 5,945 Mn, PAT increased 33% to Rs. 773 Mn
20th Jul, 2021
Syngene appoints Sanjeev Sukumaran as CHRO
3rd Jun, 2021
Syngene reports revenue from operations growth of 13% in the fourth quarter; 12% for the full year
27th Apr, 2021
Syngene International extends long term research collaboration with Bristol Myers Squibb until 2030
26th Apr, 2021
Inauguration of COVID-19 Vaccination Centre at Syngene International Limited, Biocon Group of Companies
12th Apr, 2021
Syngene announces Q3 FY21 results
20th Jan, 2021
Syngene and PharmAust collaborate to manufacture GMP-grade Monepantel for Human Clinical Trials
23rd Dec, 2020
Syngene and Deerfield Discovery and Development (3DC) sign 5-year strategic collaboration
19th Nov, 2020
Syngene reports second quarter revenue from operations at Rs. 519 Cr, up 12% year on year
21st Oct, 2020

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements.

To find out more, read our Privacy Policy and Cookies Policy.

To download, Please share your details

To download, Please share your details